Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: ANIK stock price vs MAN: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at MAN's multiple
Needs MAN P/S.
Implied fair value · at ANIK's multiple
Needs ANIK P/S.
Metric by metric
Live quote
Price unavailable
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: ANIK FY 2025 (ended Dec 31, 2025) · MAN FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
Anika Therapeutics, Inc. · implied price per share
Bear
-$0.46
Base
-$0.55
Bull
-$0.63
MANPOWERGROUP INC. · implied price per share
Bear
-$162.08
Base
-$190.68
Bull
-$219.28
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.07x
1.10x
Net debt / EBITDA
Leverage against operating earnings
30.49x
9.93x
Cash and equivalents
Liquid reserves on the balance sheet
$81.17M
$871.40M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
$9.60M
$2.27B
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe ANIK can stabilize revenue and convert its strong gross margin into positive operating profit, then hold or selectively accumulate despite the valuation gap, because the current stock price is already above the historical band and MAN-based P/S model assumes much weaker fundamentals than ANIK may ultimately deliver.
On a P/S basis, ANIK appears dramatically expensive versus MAN, with an implied price of $1.18 versus the current $20.73, or -94.3% downside. However, MAN range is extremely wide and the two companies operate in very different industries, which limits the direct relevance of the comparison.
Supporting Metrics
